摘要
目的探讨奥希替尼联合培美曲塞^(+)卡铂单用与联用治疗晚期非鳞状非小细胞肺癌患者临床疗效及对免疫功能的影响。方法选取2016年12月~2020年12月我院收治的晚期非鳞状非小细胞肺癌患者168例,根据随机数字表法将患者分为A组(奥希替尼组)、B组(培美曲塞^(+)卡铂组)及联合组(奥希替尼联合培美曲塞^(+)卡铂组),每组56例。A组给予奥希替尼治疗,B组给予培美曲塞^(+)卡铂治疗,联合组则给予奥希替尼联合培美曲塞^(+)卡铂治疗,对3组治疗疗效进行比较分析。结果联合组疾病控制率均高于A组与B组(P<0.05);免疫功能相关指标与治疗前相比,3组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均明显提高(P<0.05),CD8^(+)水平降低(P<0.05),其中联合组上述各指标改善程度较A、B两组更优,差异有统计学意义(P<0.05);联合组不良反应总发生率与A组、B组比较差异无统计学意义(P>0.05)。结论晚期非鳞状非小细胞肺癌患者给予奥希替尼联合培美曲塞^(+)卡铂治疗临床效果较好,能够改善患者免疫功能,疗效安全可靠,可在临床推广应用。
Objective To compare the clinical efficacy and immune function of oxitinib and Pemetrexed^(+)carboplatin in the treatment of advanced non squamous non-small cell lung cancer.Methods From December 2016 to December 2020,168 patients with advanced non squamous non-small cell lung cancer in our hospital were selected.According to the random number table method,the patients were divided into group A(56 cases),Pemetrexed^(+)carboplatin group(56 cases)and group B(56 cases).Group A was only treated with oxitinib,group B was only treated with pemetrexed^(+)carboplatin,and the combined group was treated with oxitinib combined with pemetrexed^(+)carboplatin.Results The disease control rate of the combined group is higher than that of group A and group B(P<0.05).Compared with before treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the three groups were significantly increased(P<0.05),and the level of CD8^(+)was decreased(P<0.05).The improvement degree of the above indexes in the combination group was significantly different from that in the a and B groups(P<0.05).There was no significant difference in the total incidence of adverse reactions between group A and group B(P>0.05).Conclusion The treatment of advanced non squamous non-small cell lung cancer patients with oxalitinib combined with Pemetrexed^(+)carboplatin can achieve good clinical effect,can improve the immune function of patients,the curative effect is safe and reliable,and can bePemetrexed^(+)carboplatin in clinical.
作者
麻发强
陆方阳
赵莉莉
廖光辉
杨杭丽
MA Faqiang;LU Fangyang;ZHAO Lili;LIAO Guanghui;YANG Hangli(Department of Thoracic Oncology,The Second Affiliated Hospital of Guizhou Medical University,Kaili 556000,Guizhou,China)
出处
《西部医学》
2022年第11期1679-1682,共4页
Medical Journal of West China
关键词
非鳞状非小细胞肺癌
奥希替尼
培美曲塞+卡铂
临床疗效
免疫状态
Non-squamous non-small cell lung cancer
Osimertinib
Pemetrexed+carboplatin
Clinical effect
Immune status
